Effects of Interleukin-13 and Montelukast on the Expression of Zonula Occludens-1 in Human Podocytes.
10.3349/ymj.2015.56.2.426
- Author:
Se Jin PARK
1
;
Moin A SALEEM
;
Ja Ae NAM
;
Tae Sun HA
;
Jae Il SHIN
Author Information
1. Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Interleukin-13;
zonula occludens-1;
podocytes;
leukotriene receptor antagonists
- MeSH:
Acetates/*pharmacology;
Blotting, Western;
Dose-Response Relationship, Drug;
Humans;
Interleukin-13/*pharmacology;
Leukotriene Antagonists/*pharmacology;
Microscopy, Confocal;
Podocytes/*drug effects/metabolism;
Proteinuria/pathology;
Quinolines/*pharmacology;
Tight Junctions;
Zonula Occludens-1 Protein/*metabolism
- From:Yonsei Medical Journal
2015;56(2):426-432
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The aim of this study was to investigate whether pathologic changes in zonula occludens-1 (ZO-1) are induced by interleukin-13 (IL-13) in the experimental minimal-change nephrotic syndrome (MCNS) model and to determine whether montelukast, a leukotriene receptor antagonist, has an effect on ZO-1 restoration in cultured human podocytes. MATERIALS AND METHODS: Human podocytes cultured on bovine serum albumin-coated plates were treated with different doses of IL-13 and montelukast and then examined for distribution using confocal microscopy and for ZO-1 protein levels using Western blotting. RESULTS: ZO-1 was internalized and shown to accumulate in the cytoplasm of human podocytes in an IL-13 dose-dependent manner. High doses (50 and 100 ng/mL) of IL-13 decreased the levels of ZO-1 protein at 12 and 24 h (both p<0.01; n=3), which were significantly reversed by a high dose (0.5 microM) montelukast treatment (p<0.01; n=3). CONCLUSION: Our results suggest that IL-13 alters the expression of ZO-1, and such alterations in the content and distribution of ZO-1 may be relevant in the pathogenesis of proteinuria in the MCNS model.
